Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $124,708.92 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin W. Juvenal sold 3,507 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the sale, the insider now directly owns 54,178 shares of the company’s stock, valued at approximately $1,926,569.68. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Castle Biosciences Trading Up 2.0 %

NASDAQ CSTL opened at $33.31 on Friday. The firm’s 50 day moving average price is $30.78 and its two-hundred day moving average price is $25.72. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.92 and a current ratio of 8.12. Castle Biosciences, Inc. has a twelve month low of $16.20 and a twelve month high of $35.84. The stock has a market cap of $919.69 million, a price-to-earnings ratio of 166.56 and a beta of 0.99.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.50% and a net margin of 1.95%. The business had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. During the same quarter in the previous year, the company posted ($0.26) earnings per share. Equities analysts anticipate that Castle Biosciences, Inc. will post -0.58 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on CSTL shares. Stephens reiterated an “overweight” rating and set a $37.00 price target on shares of Castle Biosciences in a research report on Tuesday, August 6th. Canaccord Genuity Group raised their target price on Castle Biosciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Lake Street Capital upped their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. KeyCorp lifted their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Scotiabank raised their price target on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $37.88.

Hedge Funds Weigh In On Castle Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its holdings in Castle Biosciences by 89.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 10,862 shares of the company’s stock worth $241,000 after buying an additional 5,123 shares during the last quarter. Norden Group LLC bought a new position in shares of Castle Biosciences during the 1st quarter valued at $547,000. GSA Capital Partners LLP lifted its stake in shares of Castle Biosciences by 9.0% in the 1st quarter. GSA Capital Partners LLP now owns 52,448 shares of the company’s stock valued at $1,162,000 after purchasing an additional 4,352 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in shares of Castle Biosciences in the 1st quarter valued at $249,000. Finally, Vanguard Group Inc. boosted its holdings in Castle Biosciences by 2.2% in the first quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock worth $33,096,000 after purchasing an additional 32,695 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.